Shares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as $68.42 and last traded at $68.43, with a volume of 1617229 shares trading hands. The stock had previously closed at $69.94.
Analysts Set New Price Targets
Several research firms have weighed in on GILD. Royal Bank of Canada lowered their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 14th. StockNews.com raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 26th. Mizuho decreased their price objective on Gilead Sciences from $101.00 to $90.00 and set a "buy" rating for the company in a report on Thursday, February 22nd. Oppenheimer lowered their price objective on Gilead Sciences from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, February 12th. Finally, Wells Fargo & Company cut their target price on Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating on the stock in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $85.36.
Get Our Latest Report on GILD
Gilead Sciences Stock Down 2.6 %
The stock has a market capitalization of $84.81 billion, a P/E ratio of 15.14, a P/E/G ratio of 0.88 and a beta of 0.19. The stock's 50-day moving average price is $73.36 and its two-hundred day moving average price is $76.98. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The firm had revenue of $7.12 billion during the quarter, compared to analysts' expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business posted $1.67 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.
Gilead Sciences Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.52%. The ex-dividend date was Thursday, March 14th. Gilead Sciences's dividend payout ratio is presently 68.44%.
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company's stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the transaction, the chief financial officer now directly owns 101,534 shares of the company's stock, valued at $8,709,586.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,000 shares of company stock worth $721,180. Corporate insiders own 0.29% of the company's stock.
Hedge Funds Weigh In On Gilead Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. PCA Investment Advisory Services Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at about $25,000. OFI Invest Asset Management purchased a new position in shares of Gilead Sciences during the third quarter worth approximately $26,000. Tompkins Financial Corp lifted its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $29,000. Finally, Private Wealth Management Group LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
